IMMUNOTHERAPY

Second-line platinum plus pemetrexed produced an 11.5-month median OS and 72% disease control after first-line nivolumab/ipilimumab in pleural mesothelioma.

The FDA has granted fast track designation to PLN-101095 plus pembrolizumab for ICI-refractory advanced or metastatic solid tumors.

The individualized neoantigen therapy intismeran autogene improved recurrence-free survival over pembrolizumab alone in patients with fully resected melanoma.

An analysis found that postprogression access to effective therapy was associated with smaller OS benefits in targeted therapy trials but not in immunotherapy trials.

EIK1001, an agonist of TLR 7 and 8, is being investigated in first-line advanced melanoma in combination with pembrolizumab.

FDA approves a new rituximab biosimilar, boosting CD20 therapy options and market competition for B-cell cancers and autoimmune diseases in the US.

SER-155 led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors.

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

Results of a single-center study showed positive outcomes of reduced-intensity conditioning for tumor-infiltrating lymphocytes in melanoma.

During a live event, Daniel Olson, MD, reviewed a patient case of recurrent melanoma with brain metastases and addressed treatment options.

Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states.

Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, frail patients.

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.

Circulating tumor DNA showed potential as a dynamic biomarker in assessing response to immune checkpoint inhibitors in melanoma.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

The LARA trial reveals promising results for pembrolizumab and lenvatinib in treating recurrent clear cell gynecological cancer, showcasing effective antitumor activity.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.